HemoNED presented at EAHAD congress
The annual congress of the European Association for Haemophilia and Allied Disorders (EAHAD) was this year from 2-4 February 2022 (online).
During the congress, HemoNED provided a short presentation on the use of emicizumab in the Netherlands. Numbers from the Dutch Hemophilia Registry and the VastePrik app showed that 28% of the people with Hemophilia A on prophylaxis are using emicizumab. Emi patients tend to be younger and patient/parent preference was the main reason for starting emicizumab.
The full abstract can be found at the page Publications.